SANGAMO THERAPEUTICS, INC
Close on Oct 19, 2026
- Market cap
- $39.43M
- P/E (TTM)
- –
- Dividend yield
- –
About Sangamo Therapeutics
Biological Products, (No Diagnostic Substances), SIC 2836
Sangamo Therapeutics, Inc. is a biotechnology company that researches and develops genomic medicines and gene therapy product candidates. The company focuses on developing therapies utilizing its zinc finger technology platform, zinc finger transcriptional regulators, and capsid delivery technologies. Its clinical-stage and core preclinical programs include development candidates for rare genetic conditions and neurological indications, such as isaralgagene civaparvovec for Fabry disease and a hemophilia A program. Sangamo targets patients with genetic and neurodevelopmental conditions and works directly with major pharmaceutical and biotechnology partners, licensing its technology assets and collaborating on clinical development.
The company operates out of principal executive offices and facilities located in Richmond, California, and maintains additional office and laboratory facilities in Brisbane, California. Sangamo also conducted restructuring activities involving operations in France. It partners globally with multinational pharmaceutical companies across the United States and international markets.
Summary of the business section of Sangamo Therapeutics's latest annual report, written by StockData.
Company profile
Company
- Legal name
- SANGAMO THERAPEUTICS, INC
- Founded
- 1995
- Headquarters
- Richmond, CA
- Address
- 501 Canal Blvd. 94084
- Phone
- (510) 970-6000
- Website
- www.sangamo.com
- Employees
- 142, Dec 31, 2025
- Industry
- Biological Products, (No Diagnostic Substances)
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- Ernst& Young LLP, San Mateo, California
Stock & identifiers
- Ticker
- SGMOQ
- Exchange
- OTC
- IPO date
- Apr 6, 2000
- Shares outstanding
- 414M, May 11, 2026
- Public float
- $152.67M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- SEC CIK
- 1001233
- CUSIP
- 800677106
- ISIN
- US8006771062
- LEI
- 2549006WMRKRC4G32Z67
- EIN
- 68-0359556
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Sandy Macrae | PRESIDENT, CEO AND DIRECTOR | 1,895,043 |
| Nikunj Jain | Principal Accounting Officer | 235,292 |
| Gregory D. Davis | Head of Research & Technology | 113,654 |
| Nathalie Dubois-Stringfellow | SVP-CHIEF DEVELOPMENT OFFICER | 328,733 |
| Scott B. Willoughby | SVP, CHIEF LEGAL OFFICER, SECY | 647,370 |
| Prathyusha Duraibabu | PRINCIPAL FINANCIAL OFFICER | 660,042 |
| Robert Carey | Director | 99,600 |
| Margaret A. Horn | Director | 82,650 |
| Kenneth J. Hillan | Director | 99,600 |
| Karen L. Smith | Director | 102,100 |
| James R. Meyers | Director | 99,600 |
| Courtney Beers | Director | 82,650 |
| H. Stewart Parker | Director | 112,600 |
| John Markels | Director | 96,384 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2024 Alexander D. Macrae | $2.46M | $3.97M | $1.15M | $14 | – |
| FY2023 Alexander D. Macrae | $2.39M | -$340.20K | $1.04M | $7 | – |
| FY2022 Alexander D. Macrae | $4.81M | $967.86K | $1.47M | $42 | – |
| FY2021 Alexander D. Macrae | $4.74M | -$1.61M | $1.27M | $90 | $126 |
| FY2020 Alexander D. Macrae | $3.84M | $9.63M | $1.70M | $186 | $126 |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Employees
Headcount reported in annual reports
“As of March 27, 2026, we had 142 full time employees located in the United States and the United Kingdom.”
Corporate history
Events identified from SEC filings